Free tool
FAERS Monitor: Bavencio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761049 or its brand name (Bavencio, Avelumab). Reports on generic versions are filed under their own applications.
Reports
4,102
Serious
3,741
91% of reports
Hospitalization
1,807
Death reported
946
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression386
- death377
- off label use239
- diarrhoea171
- pyrexia150
- infusion related reaction148
- fatigue136
- neoplasm progression125
- dyspnoea111
- nausea110
- chills107
- hypertension107
- interstitial lung disease106
- rash102
- acute kidney injury89
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 13 |
| 2017 | 216 |
| 2018 | 389 |
| 2019 | 433 |
| 2020 | 446 |
| 2021 | 565 |
| 2022 | 577 |
| 2023 | 489 |
| 2024 | 438 |
| 2025 | 320 |
| 2026 | 216 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 125 | 18.5 | 15.6 | 2,048 |
| disease progressionSignal | 386 | 16.8 | 15.3 | 5,725 |
| infusion related reactionSignal | 148 | 11.5 | 9.8 | 1,406 |
| interstitial lung diseaseSignal | 106 | 11.2 | 9.3 | 980 |
| chillsSignal | 107 | 4.7 | 3.9 | 308 |
| acute kidney injurySignal | 89 | 3.0 | 2.4 | 116 |
| hypertensionSignal | 107 | 2.6 | 2.1 | 104 |
| deathSignal | 377 | 2.2 | 2.0 | 270 |
| pyrexiaSignal | 150 | 2.2 | 1.9 | 101 |
| off label use | 239 | 1.4 | 1.2 | 28 |
| diarrhoea | 171 | 1.4 | 1.2 | 16 |
| rash | 102 | 1.2 | 1.0 | 3 |
| dyspnoea | 111 | 1.0 | 0.8 | 0 |
| fatigue | 136 | 0.9 | 0.8 | 2 |
| nausea | 110 | 0.7 | 0.6 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.